Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
26 studies found for:    AMG145 | Phase 3
Show Display Options
Rank Status Study
1 Completed
Has Results
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
Condition: Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Interventions: Drug: Atorvastatin;   Biological: Evolocumab;   Other: Placebo to Evolocumab
2 Completed
Has Results
Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
Conditions: Primary Hypercholesterolemia;   Mixed Dyslipidemia
Interventions: Biological: Evolocumab AMD;   Biological: Evolocumab AI/pen
3 Completed
Has Results
Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen
Conditions: Primary Hypercholesterolemia;   Mixed Dyslipidemia
Interventions: Biological: Evolocumab Pre-filled Syringe;   Biological: Evolocumab AI/pen
4 Recruiting Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH).
Condition: Familial Hypercholesterolemia
Intervention: Biological: evolocumab (AMG 145)
5 Active, not recruiting Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Condition: Hypercholesterolemia
Interventions: Biological: evolocumab (AMG 145);   Other: Low Density Lipoprotein Cholesterol (LDL-C) Apheresis
6 Not yet recruiting Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia
Condition: Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Interventions: Drug: Repatha (Evolocumab);   Drug: Placebo
7 Recruiting A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia
Conditions: Hypercholesterolemia;   Mixed Dyslipidemia;   Type 2 Diabetes
Interventions: Biological: Evolocumab;   Other: Placebo to Evolocumab
8 Active, not recruiting Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab
Condition: Hypercholesterolemia
Intervention: Biological: Evolocumab
9 Completed GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
Condition: Hypercholesterolemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo
10 Active, not recruiting Open Label Study of Long Term Evaluation Against LDL-C Trial-2
Condition: Hyperlipidemia and Mixed Dyslipidemia
Interventions: Biological: evolocumab (AMG 145) and standard of care;   Other: Standard of care
11 Completed
Has Results
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
Condition: Hyperlipidemia
Interventions: Biological: Evolocumab;   Drug: Placebo
12 Completed
Has Results
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
Condition: Hypercholesterolemia
Interventions: Biological: Evolocumab;   Biological: Placebo;   Drug: Atorvastatin;   Drug: Ezetimibe;   Other: Diet Only
13 Recruiting Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4
Condition: Hypercholesterolemia
Interventions: Biological: Evolocumab;   Drug: Ezetimibe
14 Completed
Has Results
Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
Condition: Primary Hyperlipidemia and Mixed Dyslipidemia
Interventions: Biological: Evolocumab;   Drug: Atorvastatin;   Drug: Placebo to Evolocumab;   Drug: Placebo to Atorvastatin
15 Completed
Has Results
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
Condition: Hyperlipidemia
Interventions: Biological: Evolocumab;   Drug: Placebo to Evolocumab;   Drug: Ezetimibe;   Drug: Placebo to Ezetimibe
16 Recruiting Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
Condition: Dyslipidemia
Intervention: Biological: Evolocumab
17 Recruiting A Double-blind, Randomized Study in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia
Condition: Diabetes, Hyperlipidemia, Mixed Dyslipidemia
Interventions: Biological: Evolocumab (AMG 145);   Drug: Atorvastatin;   Other: Placebo
18 Recruiting Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders
Condition: Heterozygous Familial Hypercholesterolemia
Interventions: Drug: Evolocumab;   Drug: Placebo
19 Completed
Has Results
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
Condition: Hyperlipidemia
Interventions: Biological: Evolocumab;   Drug: Ezetimibe;   Biological: Placebo to Evolocumab;   Other: Placebo to Ezetimibe
20 Completed Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Condition: Dyslipidemia
Interventions: Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.